Belangrijkste concepten
NK cell therapy shows promise in treating Alzheimer's disease by reducing amyloid and tau proteins, improving cognitive function, and reducing neuroinflammation.
Samenvatting
The investigational NK cell therapy, SNK01, developed by NKGen Biotech, has shown promise in treating Alzheimer's disease. The therapy involves enhanced NK cells that have increased cytotoxicity and activating receptor expression. The therapy aims to reduce amyloid and tau proteins, decrease neuroinflammation, and improve cognitive function in patients with Alzheimer's disease. The phase 1 clinical trial demonstrated safety, tolerability, and exploratory efficacy of SNK01 in patients with varying stages of Alzheimer's disease. The therapy successfully activated and expanded NK cells in all patients without any adverse events. Positive results from the trial have led to FDA approval for a phase 1/2a study in patients with moderate Alzheimer's disease.
Key Highlights:
- SNK01, an autologous NK cell therapy, shows promise in treating Alzheimer's disease.
- Enhanced NK cells reduce amyloid and tau proteins, improve cognitive function, and decrease neuroinflammation.
- Phase 1 trial results demonstrate safety, tolerability, and efficacy of SNK01 in patients with Alzheimer's disease.
- NK cell therapy may complement existing anti-amyloid and anti-tau therapies for Alzheimer's disease.
Statistieken
"When we give these enhanced natural killer cells intravenously, not only do they get into the brain, but we've shown, through CSF biomarker data, that they reduce both amyloid and tau proteins, dramatically reducing the neuroinflammation," Paul Song, MD, chief executive officer of NKGen Biotech, told Medscape Medical News.
"Remarkably," in the first 6 months, 90% of patients with AD demonstrated improvement or maintained stable cognitive function, based on the AD Composite Score (ADCOMS), suggesting that SNK01 may do more than simply slow disease progression, Song said.
Citaten
"When we give these enhanced natural killer cells intravenously, not only do they get into the brain, but we've shown, through CSF biomarker data, that they reduce both amyloid and tau proteins, dramatically reducing the neuroinflammation." - Paul Song, MD